Inpatient Rehab Facility Expansion And Consolidation Will Drive Future Strength

AN
AnalystConsensusTarget
Consensus Narrative from 6 Analysts
Published
02 Sep 24
Updated
07 Aug 25
AnalystConsensusTarget's Fair Value
US$18.33
35.1% undervalued intrinsic discount
07 Aug
US$11.90
Loading
1Y
-63.5%
7D
-19.5%

Author's Valuation

US$18.3

35.1% undervalued intrinsic discount

AnalystConsensusTarget Fair Value

Last Update04 Aug 25
Fair value Decreased 11%

The downward revision in Select Medical Holdings’ price target reflects a significant decline in net profit margin and a higher discount rate, resulting in a new consensus fair value of $18.33 per share.


What's in the News


  • Repurchased 5,725,708 shares for $85.04 million, completing a total buyback of 54,610,335 shares for $697.07 million under the ongoing program.
  • Reaffirmed 2025 earnings guidance with expected revenue between $5.3 billion and $5.5 billion, and fully diluted EPS between $1.09 and $1.19.
  • Dropped from multiple Russell growth and small cap indices, including Russell 3000 Growth, 2500 Growth, 2000 Growth, Small Cap Comp Growth, and related benchmarks.
  • Signed clinical affiliation agreements with five major higher education institutions to provide clinical rotation sites for nursing students through the uPLIFT program, enhancing access to practical experience in post-acute care settings.

Valuation Changes


Summary of Valuation Changes for Select Medical Holdings

  • The Consensus Analyst Price Target has significantly fallen from $20.50 to $18.33.
  • The Net Profit Margin for Select Medical Holdings has significantly fallen from 4.84% to 3.86%.
  • The Discount Rate for Select Medical Holdings has risen from 7.51% to 7.89%.

Key Takeaways

  • Strategic expansion and partnerships strengthen market presence, drive higher patient volumes, and enhance resilience amid evolving healthcare demands.
  • Operational improvements and healthcare policy trends position post-acute and rehab offerings for sustained revenue and margin growth.
  • Ongoing regulatory pressures, high debt, and shifts toward home-based care are compressing margins and threatening revenue stability across key Select Medical business segments.

Catalysts

About Select Medical Holdings
    Through its subsidiaries, operates critical illness recovery hospitals, rehabilitation hospitals, and outpatient rehabilitation clinics in the United States.
What are the underlying business or industry changes driving this perspective?
  • Expansion of inpatient rehab facilities, including new hospitals and bed additions in response to increasing demand from an aging population and chronic disease prevalence, is expected to drive higher patient volumes and top-line revenue growth over the next several years.
  • Strong demand fundamentals in critical illness recovery and rehabilitation services, supported by demographic trends and hospital system needs to decompress crowded ICUs, suggest ongoing stability in patient flows, underpinning long-term revenue and cash flow growth.
  • Continued investment in operational efficiency initiatives and system upgrades-particularly in the outpatient rehab platform-are set to enhance EBITDA margins through better scheduling, process optimization, and scalable performance improvements across a broad national clinic footprint.
  • Increased consolidation of smaller providers and successful execution of joint venture strategies with large health systems position the company to grow market share and network density, leading to improved bargaining power, reduced referral source dependency, and more resilient earnings.
  • Policy and payer shifts toward value-based and cost-effective care settings favor Select Medical's post-acute and rehab offerings, potentially boosting occupancy rates and reducing earnings volatility as payers and hospitals increasingly steer patients to these lower-cost, high-quality care environments.

Select Medical Holdings Earnings and Revenue Growth

Select Medical Holdings Future Earnings and Revenue Growth

Assumptions

How have these above catalysts been quantified?
  • Analysts are assuming Select Medical Holdings's revenue will grow by 5.1% annually over the next 3 years.
  • Analysts assume that profit margins will increase from 1.5% today to 3.9% in 3 years time.
  • Analysts expect earnings to reach $236.5 million (and earnings per share of $1.53) by about August 2028, up from $81.1 million today.
  • In order for the above numbers to justify the analysts price target, the company would need to trade at a PE ratio of 10.6x on those 2028 earnings, down from 18.3x today. This future PE is lower than the current PE for the US Healthcare industry at 20.3x.
  • Analysts expect the number of shares outstanding to decline by 4.64% per year for the next 3 years.
  • To value all of this in today's terms, we will use a discount rate of 8.46%, as per the Simply Wall St company report.

Select Medical Holdings Future Earnings Per Share Growth

Select Medical Holdings Future Earnings Per Share Growth

Risks

What could happen that would invalidate this narrative?
  • Continual regulatory pressures-particularly ongoing reductions to Medicare reimbursement rates and the recent, unexpected 20% transmittal rule impacting LTACHs-are suppressing revenue growth and compressing margins, with leadership acknowledging these headwinds are likely to persist as part of their long-term financial guidance.
  • The critical illness recovery hospital segment is facing declining revenues (down 1% YoY) and a significant drop in adjusted EBITDA (down 22% YoY), largely due to unfavorable regulatory changes in reimbursement mechanisms; ongoing pressure in this key business line threatens company-wide net margin and earnings stability.
  • The company maintains a high debt load ($1.9 billion outstanding), and while current cash flow covers operational needs and capital expenditures, rising interest expense (up $2 million YoY) and heavy ongoing capital investments for expansion could strain free cash flow and limit financial flexibility, impacting future net earnings.
  • Broader industry trends toward home-based care and telehealth pose a risk of reducing demand for facility-based services in both LTACHs and inpatient rehab hospitals, potentially constraining future patient volumes and limiting growth in revenue and operating margins.
  • Persistent dependence on government (Medicare, Medicaid) and managed care payers makes Select Medical vulnerable to further payer mix shifts, rate cuts, and preauthorization denials-especially as Medicare Advantage plans grow-introducing uncertainty in patient volume, reimbursement rates, and overall revenue predictability.

Valuation

How have all the factors above been brought together to estimate a fair value?
  • The analysts have a consensus price target of $18.333 for Select Medical Holdings based on their expectations of its future earnings growth, profit margins and other risk factors. However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $21.0, and the most bearish reporting a price target of just $14.0.
  • In order for you to agree with the analyst's consensus, you'd need to believe that by 2028, revenues will be $6.1 billion, earnings will come to $236.5 million, and it would be trading on a PE ratio of 10.6x, assuming you use a discount rate of 8.5%.
  • Given the current share price of $11.95, the analyst price target of $18.33 is 34.8% higher.
  • We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.

How well do narratives help inform your perspective?

Disclaimer

AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.

Read more narratives